Meeting Coverage
CMSC-ACTRIMS
The Joint Consortium of Multiple Sclerosis Centers and America's Committee on Treatment and Research in Multiple Sclerosis
DALLAS -- Extended-release dalfampridine (Ampyra) is approved for boosting walking speed in multiple sclerosis patients, but its benefits extend to other aspects of physical function, according to a small study reported here.
Latest CMSC-ACTRIMS Meeting Coverage
DALLAS -- Canadian multiple sclerosis patients who left the country to undergo the controversial procedure called chronic cerebrospinal venous insufficiency (CCSVI) often received poor pre- and postoperative care, but most were still relatively satisfied overall, a researcher reported here.
DALLAS -- Large proportions of patients starting on dimethyl fumarate (Tecfidera) for multiple sclerosis need additional medications to manage the drug's GI and other side effects, and a substantial minority ultimately find the drug intolerable.
Nearly 80% of multiple sclerosis patients in a large registry reported overactive bladder symptoms, and one-third of a separate cohort of newly diagnosed patients also showed urinary dysfunction, researchers reported here.